Next generation point-of-care test for therapeutic drug monitoring of adalimumab in patients diagnosed with autoimmune diseases.

导出 LinkOut

翻译打印收藏纠错

作者： Henry,Ordutowski ^[1] ; Francesco,Dal Dosso ^[1] ; Wout,De Wispelaere ^[1] ; Charlotte,Van Tricht ^[1] ; Séverine,Vermeire ^[2] ; Nick,Geukens ^[3] ; Ann,Gils ^[4] ; Dragana,Spasic ^[5] ; Jeroen,Lammertyn ^[6]

作者单位： Department of Biosystems, Biosensors Group, KU Leuven, Belgium. ^[1] Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Belgium. ^[2] Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium; PharmAbs, The KU Leuven Antibody Center, Leuven, Belgium. ^[3] Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium. ^[4] Department of Biosystems, Biosensors Group, KU Leuven, Belgium. Electronic address: dragana.spasic@kuleuven.be. ^[5] Department of Biosystems, Biosensors Group, KU Leuven, Belgium. Electronic address: jeroen.lammertyn@kuleuven.be. ^[6]

关键词 Adalimumab ELISA Plasmapheresis Point-of-care Self-powered microfluidics Therapeutic drug monitoring

主题词自身免疫疾病(Autoimmune Diseases);生物传感技术(Biosensing Techniques);药物监测(Drug Monitoring);人类(Humans);芯片实验室装置(Lab-On-A-Chip Devices);床旁诊断化验信息系统(Point-of-Care Systems)

DOI 10.1016/j.bios.2022.114189

PMID 35366427

发布时间 2022-05-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交